Targeted drug trial offers hope for kids with rare, Treatment-Resistant immune disorder
NCT ID NCT04943198
First seen Apr 10, 2026 · Last updated Apr 16, 2026 · Updated 1 time
Summary
This study aims to find the best dose and treatment schedule for the drug vemurafenib in children and young people with a rare immune disorder called histiocytosis. It is for patients whose disease has not responded to standard treatments and who have a specific genetic change (BRAF mutation). The goal is to better control the disease by personalizing treatment based on the patient's genetic profile.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mother and Child Institute
RECRUITINGWarsaw, Mazovian, 01-211, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.